PressNovember 9, 2023 Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast
PressNovember 6, 2023 Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
PressNovember 6, 2023 Sunstone Therapies Announces Start of First Study of Multiple Doses of Psilocybin in Treatment of Depression in Patients with Cancer
PressNovember 6, 2023 DEA Announces Major Increase to 2023 Production Quotas for Psilocybin, THC and Ibogaine
PressNovember 6, 2023 Red Light Holland Engages Dr. Taras Nahirny, as Advisor to Help with Distribution of Company Homogenized Psilocybin Microdosing Capsules
BlogNovember 3, 2023 Media Blames Magic Mushrooms for Pilot’s Attempt to Bring Down Plane Full of Passengers: What Really Happened?
PressNovember 3, 2023 Optimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt Financing
PressNovember 3, 2023 Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements
PressNovember 2, 2023 Reset Pharma Receives Notice of Safe to Proceed from FDA for Investigational New Drug (IND) Application for Oral Psilocybin RSTP1000
PressNovember 2, 2023 Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline
BlogNovember 1, 2023 Christi Myers Believes in the Power of Dissociative Therapy – Podcast Episode #37
PressNovember 1, 2023 Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
PressOctober 26, 2023 Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs
